Durvalumab: 15 agencies, 2018–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland) has been harder on durvalumab than on its own caseload: it refused 7 of 9 decisive submissions here (78%), against a base rate of 41% across everything it has assessed.
Assessment has run over 8.2 years, from 2018 at PBAC (Australia) to 9 Sep 2026 at NICE (England).
CIPM (Spain) changed its position: not recommended on 2 Jun 2022, recommended by 20 May 2026, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for durvalumab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 80 of 108 records date from 2023 or later.
The programme is broad: 33 distinct indication wordings are recorded for durvalumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
12 of these 108 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess durvalumab, in 2018; DMC (Denmark) did not open a file until 5 Dec 2024 — a wide spread of 6.4 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 9 years in total.
14 of the 15 agencies here assessed durvalumab more than once, PBAC (Australia) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
durvalumab has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for durvalumab reads 59 recommended, 18 not recommended, 11 deferred to NICE and 8 restricted, with 12 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 16 Jul 2026 | Advies - vergoed durvalumab (Imfinzi®) voor de behandeling van beperkt stadium kleincellige longkanker | reimbursed | source |
| DMC (Denmark) | 24 Jun 2026 | Durvalumab i kombination med FLOT-kemoterapi som neoadjuverende og adjuverende behandling, efterfulgt af adjuverende mon… | Anbefalet | source |
| AOTMIT (Poland) | 16 Oct 2025 | programu lekowego B.6 „Leczenie chorych na raka płuca (ICD-10 C34) oraz międzybłoniaka opłucnej (ICD-10 C45) | recommended conditionally | source |
| SMC (Scotland) | 9 Dec 2024 | In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults wi… | not recommended | source |
| PBAC (Australia) | 2022 | Small cell lung cancer | The PBAC advised that the November 2020 recommendation be extended for 6 months (if listin… | source |
103 further decisions for durvalumab, across 15 agencies, are not shown here. They include the most recent record on file, 9 Sep 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 85 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
- everolimus — same ATC class L01X — Antineoplastics
Coverage: 108 decisions for durvalumab from 15 agencies, 2018 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.